TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01128920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin and Needle Hygiene Intervention
Description: Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention - assessment-only condition
Description: No intervention is assigned in this condition
Study: NCT03954808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy within a specific program
Study: NCT04398147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration
Study: NCT00465283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
Study: NCT02449447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT based on behavioral activation and cognitive therapy techniques including homework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in primary care including antidepressants and counselling
Study: NCT02892708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: partial or complete resection followed by radiotherapy
Study: NCT04515563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-frequency, vigorous-intensity walking group
Description: thrice-a-week walking exercise at vigorous intensity
Study: NCT01761786

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotyping
Description: CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
Study: NCT01274130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diavex 1000mg on Day1 and 750mg on Day2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diavex 1000mg on Day1 and 750mg on Day2
Study: NCT01529190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01242943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-L19SIP Radioimmunotherapy (RIT)
Description: Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167.
Study: NCT03150680

Intervention type: GENETIC
Intervention: SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins
Description: Genotyping will be carried out by Next-Generation Sequencing (NGS)

Intervention type: GENETIC
Intervention: SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins
Description: Genotyping will be carried out by Next-Generation Sequencing (NGS)

Intervention type: GENETIC
Intervention: SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins
Description: Genotyping will be carried out by Next-Generation Sequencing (NGS)
Study: NCT01120171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated doxorubicin
Description: Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity.
Study: NCT00312975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Given intravenously every 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best supportive care
Description: As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
Study: NCT04305899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days
Study: NCT04398147

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT02892708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy after a brain biopsy
Study: NCT02801227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
Study: NCT04305899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet formulation 2
Description: Specified dose on specified days
Study: NCT02801227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Description: PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
Study: NCT00792428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Transcranial Direct Current Stimulation
Description: A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: A sham current runs between two electrode positions and might affect the underlying brain tissue.
Study: NCT03938948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser/light therapy
Description: Participants will wear light therapy devices for 14 weeks
Study: NCT02674243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodopovidone solution
Description: In this group, iodopovidone solution will be used as pleurodesis substance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: In this group, Talc will be used as pleurodesis substance
Study: NCT03672617

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion.

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion.
Study: NCT03670173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osalmid
Description: Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
Study: NCT02388230

Intervention type: DEVICE
Intervention: Ultrasound imaging

Intervention type: DEVICE
Intervention: Ultrasound imaging
Study: NCT04398147

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT00870558

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ethiodized oil
Description: Given as an intra-arterial infusion
Study: NCT00050427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET743
Description: 580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET743
Description: 1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Study: NCT00206518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere/Docetaxel
Description: Taxotere

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin/Cytoxan
Description: Adriamycin/Cytoxan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
Study: NCT03598777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
Study: NCT02232789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephedrone
Description: Single oral dose mephedrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine
Description: Single oral dose MDMA
Study: NCT00870558

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 ethiodized oil
Description: Given as an intra-arterial infusion
Study: NCT02232789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oal dose placebo
Study: NCT02850614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaming application to encourage physical activity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Study: NCT03032887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voice prompts
Description: voice prompts on disinfectant dispenser

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: agitation
Description: Education, reminders and optimising materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: agitation
Description: Education, reminders and optimising materials
Study: NCT00003937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04650646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-related hypoglycaemia
Description: Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia under resting conditions
Description: Hypoglycaemia induced by intravenous insulin during bed rest.
Study: NCT05271890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate non-surgical periodontal treatment and oral hygiene instructions
Study: NCT02263703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
Study: NCT02622867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 3547
Description: During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
Study: NCT03253354

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation
Study: NCT00675233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Escalating light doses with 665 nm light
Study: NCT02690740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml
Description: see information in arm/group descriptions
Study: NCT03873805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT01464450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Single 20 mg-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Single 20 mg-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Single 20 mg-dose
Study: NCT02596282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal circumcision under topical anesthesia
Description: The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care.
Study: NCT01371565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: mifepristone at doses from 300mg/day up to 1200mg/day
Study: NCT00617903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 15% foam to be applied topically twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Active-ingredient-free vehicle to be applied topically twice daily